|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
HK1199736A1
(en)
*
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US8796405B2
(en)
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013158141A1
(en)
*
|
2012-04-18 |
2013-10-24 |
Arrowhead Research Corporation |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
CA3261641A1
(en)
|
2013-03-13 |
2025-06-12 |
Oncour Pharma, Inc. |
Immune-modifying particles for the treatment of inflammation
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PE20152002A1
(es)
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
|
SG11201600379TA
(en)
|
2013-08-07 |
2016-02-26 |
Arrowhead Res Corp |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
EP3647318B1
(en)
|
2014-04-28 |
2021-06-30 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
RS59182B1
(sr)
|
2014-05-01 |
2019-10-31 |
Ionis Pharmaceuticals Inc |
Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
|
|
ES2812099T3
(es)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
|
|
ES2844593T3
(es)
|
2014-05-01 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
WO2016196239A1
(en)
|
2015-05-29 |
2016-12-08 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression of hif2alpha
|
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
|
SG10201913209WA
(en)
|
2015-09-24 |
2020-02-27 |
Ionis Pharmaceuticals Inc |
Modulators of kras expression
|
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
BR112018008090A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
|
MA47016A
(fr)
|
2015-10-22 |
2018-08-29 |
Modernatx Inc |
Vaccins contre les virus respiratoires
|
|
CA3003103A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
JP6925688B2
(ja)
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス， インコーポレイテッド |
水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
HRP20241087T1
(hr)
|
2015-11-06 |
2024-11-08 |
Ionis Pharmaceuticals, Inc. |
Konjugirani protusmisleni spojevi za upotrebu u terapiji
|
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
MX2018009854A
(es)
|
2016-03-07 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos dirigidos para compuestos terapeuticos.
|
|
CA3023764A1
(en)
|
2016-06-06 |
2017-12-14 |
Arrowhead Pharmaceuticals, Inc. |
5'-cyclo-phosphonate modified nucleotides
|
|
IL264216B2
(en)
|
2016-07-15 |
2024-04-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulation of smn2
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
CN116832169A
(zh)
|
2016-09-02 |
2023-10-03 |
箭头药业股份有限公司 |
靶向配体
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
MX2019008252A
(es)
|
2017-01-10 |
2019-09-06 |
Arrowhead Pharmaceuticals Inc |
Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso.
|
|
CN119548520A
(zh)
|
2017-01-30 |
2025-03-04 |
箭头药业股份有限公司 |
用于抑制因子xii基因表达的组合物和方法
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
KR20200024793A
(ko)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
JOP20200054A1
(ar)
|
2017-09-11 |
2020-03-10 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
|
|
AU2018331383B2
(en)
|
2017-09-14 |
2024-12-05 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
|
|
WO2019079294A1
(en)
|
2017-10-17 |
2019-04-25 |
Arrowhead Pharmaceuticals, Inc. |
RNAI-BASED AGENTS AND COMPOSITIONS FOR INHIBITING ASIALOGLYCOPROTEIN RECEPTOR 1 RECEPTOR 1
|
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
CA3109553A1
(en)
|
2018-09-19 |
2020-03-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
SG11202106378VA
(en)
|
2018-12-21 |
2021-07-29 |
Ionis Pharmaceuticals Inc |
Modulators of hsd17b13 expression
|
|
CA3120580A1
(en)
|
2019-01-09 |
2020-07-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
TWI872048B
(zh)
|
2019-02-07 |
2025-02-11 |
美商艾羅海德製藥公司 |
用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
|
|
CA3143679A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Ｐｎｐｌａ３発現のモジュレーター
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
EP4125932A2
(en)
|
2020-03-26 |
2023-02-08 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods of use
|
|
JP2023522957A
(ja)
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング， インコーポレイテッド |
二機能性分子およびその使用方法
|
|
JP2023541415A
(ja)
|
2020-09-11 |
2023-10-02 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
治療薬の送達用脂質複合体
|
|
TW202227627A
(zh)
|
2020-09-11 |
2022-07-16 |
美商愛羅海德製藥公司 |
用於抑制DUX4表現之RNAi藥劑、其組合物及使用方法
|
|
CA3189077A1
(en)
|
2020-09-11 |
2022-03-17 |
Xiaokai Li |
Skeletal muscle delivery platforms and methods of use
|
|
MX2023005736A
(es)
|
2020-11-18 |
2023-05-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la expresion de angiotensinogeno.
|
|
MX2023011909A
(es)
|
2021-04-08 |
2023-10-18 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.
|
|
IL307885A
(en)
|
2021-04-23 |
2023-12-01 |
Ganna Bio Inc |
Nucleic acids with different glycans, preparation methods and therapeutic uses
|
|
PE20250265A1
(es)
|
2021-05-28 |
2025-01-29 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inhibir la expresion de mucina 5ac (muc5ac), composiciones de estos y metodos de uso
|
|
US11549112B1
(en)
|
2021-06-21 |
2023-01-10 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
IL311518A
(en)
|
2021-10-01 |
2024-05-01 |
Adarx Pharmaceuticals Inc |
Preparations that modulate perkalkerine and methods of using them
|
|
EP4482962A1
(en)
|
2022-02-24 |
2025-01-01 |
IO Biotech ApS |
Nucleotide delivery of cancer therapy
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
CN119730859A
(zh)
|
2022-06-15 |
2025-03-28 |
箭头药业股份有限公司 |
用于抑制超氧化物歧化酶1(SOD1)表达的RNAi剂、其组合物及使用方法
|
|
AU2024240837A1
(en)
|
2023-03-21 |
2025-09-11 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
|
|
EP4698652A2
(en)
|
2023-04-20 |
2026-02-25 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
KR20260021635A
(ko)
|
2023-05-12 |
2026-02-13 |
아다르엑스 파마슈티컬스, 인크. |
Nmda 리간드 접합 화합물 및 이의 용도
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
TW202506137A
(zh)
|
2023-06-20 |
2025-02-16 |
美商雅迪克斯製藥公司 |
Ｌｒｒｋ２調節組合物及其使用方法
|
|
WO2025049773A1
(en)
|
2023-08-30 |
2025-03-06 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
TW202530408A
(zh)
|
2023-09-29 |
2025-08-01 |
美商英西特羅公司 |
用於治療非酒精性脂肪肝病的組合物與方法
|
|
WO2025137384A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Methods and reagents for improved oligonucleotide synthesis
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
WO2025212467A1
(en)
|
2024-03-31 |
2025-10-09 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
US20260021195A1
(en)
|
2024-06-20 |
2026-01-22 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|